2015 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2012 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Networking Rank (Reputation): | > 1000 |
2011 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2010 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 5
As coordinator: 0
As participant: 5
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2015 | 0 | 3.782.583 | 223.914 | 1 | ||
2013 | 0 | 3.971.184 | 173.823 | 1 | ||
2012 | 0 | 5.976.298 | 398.420 | 1 | ||
2011 | 0 | 3.740.034 | 211.419 | 1 | ||
2010 | 0 | 1.680.248 | 94.772 | 1 |
Total number of partners: 50
Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 47
Frequent / Rare Partner Ratio: 0.06
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2015-01-01 | Chromatin Dynamics in Development and Disease | Chromatin3D | participant | 3.782.583 | 12 |
2013-09-01 | Control of metabolic and inflammatory pathways by nuclear receptors | NR-NET | participant | 3.971.184 | 10 |
2012-11-01 | "Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)" | TARGETAMD | participant | 5.976.298 | 15 |
2011-11-01 | Transglutaminase in disease: a novel therapeutic target? | TRANSPATH | participant | 3.740.034 | 11 |
2010-07-01 | The Commercialisation of Transglutaminase | TRANSCOM | participant | 1.680.248 | 7 |